Nuvaira, Inc.

Nuvaira, Inc. is a medical technology company focused on developing innovative solutions for chronic obstructive pulmonary disease (COPD) through its dNerva Lung Denervation System, aimed at enhancing patient outcomes. Founded in 2008 and headquartered in Minneapolis, US, Nuvaira, Inc. specializes in creating advanced therapeutic options for COPD.

The company underwent a strategic pivot, changing its name from Holair to Nuvaira, reflecting its focus on the dNerva system. The CEO is Dennis D. , who has a history of involvement in medical technology ventures. Nuvaira has raised a total of USD 15.

12 mn, with the most recent funding being a Series F round in November 2023, which contributed to the total amount raised and the company's current valuation of USD 150. 82 mn. Nuvaira, Inc. specializes in the dNerva Lung Denervation System, a catheter-based technology designed for a one-time, outpatient bronchoscopic procedure.

This system aims to disrupt nerve connections to and from the lungs, addressing the challenges associated with COPD by targeting neural hyperactivity. Currently, the dNerva system is under clinical investigation and not yet commercially available in the US, with plans to target regions with high COPD prevalence. Nuvaira generates revenue through the dNerva Lung Denervation System, focusing on a B2B model that engages hospitals and outpatient clinics specializing in pulmonary care. Revenue is derived from selling the dNerva system and associated services, with prices structured around individual procedures.

The revenue potential will depend on successful implementation following regulatory approval, as the system is still under clinical investigation. In December 2023, Nuvaira, Inc. successfully raised USD 15. 12 mn in Series F funding, as part of a larger USD 17.

25 mn Series F round. The funds will support the ongoing development of the dNerva system and its regulatory approval processes. The company plans to expand into new markets with high COPD patient populations, although specific regions have not been disclosed.